Xeris Biopharma Holdings, Inc.XERSNASDAQ

Revenue (LTM)

$292M

+43.7% YoY

Net Income (LTM)

$554000

+101.0% YoY

Free Cash Flow

$28M

Revenue CAGR (5Y)

+70.2%

Marginsimproving

FCFTurned positive

Now profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	50	110↑122.3%	164↑48.7%	203↑23.9%	292↑43.7%
Gross Profit	36	88↑141.5%	135↑54.4%	166↑22.9%	238↑43.4%
Operating Income	-115	-82↑28.8%	-44↑46.3%	-34↑23.5%	25↑174.0%
Net Income	-123	-95↑22.9%	-62↑34.2%	-55↑11.9%	1↑101.0%
EBITDA	-114	-69↑39.0%	-24↑65.8%	-14↑41.0%	13↑190.8%
EPS Diluted	-1.55	-0.70↑54.8%	-0.45↑35.7%	-0.37↑17.8%	0.00↑100.9%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	67	122↑81.3%	67↓44.7%	72↑6.2%	111↑55.0%
Total Current Assets	143	187↑31.0%	156↓16.4%	168↑7.3%	240↑43.3%
Total Assets	304	345↑13.2%	323↓6.4%	323↑0.1%	384↑18.7%
Total Current Liabilities	79	74↓6.9%	95↑29.3%	100↑5.5%	110↑9.1%
Total Liabilities	209	299↑43.1%	329↑10.0%	353↑7.1%	370↑4.9%
Total Equity	95	45↓52.6%	-7↓115.0%	-30↓336.7%	14↑146.2%
Total Debt	88	198↑124.9%	229↑15.7%	271↑18.4%	38↓86.1%
Net Debt	21	76↑265.9%	162↑112.6%	200↑23.5%	-73↓136.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-96	-103↓7.7%	-47↑54.3%	-37↑21.4%	29↑177.4%
Capital Expenditure	-1	-1↓0.0%	-2↓331.9%	-1↑61.6%	-1↑19.8%
Free Cash Flow	-103	-103↓0.0%	-49↑52.3%	-38↑23.2%	28↑173.8%
Stock-Based Comp	11	12↑6.8%	11↓11.9%	18↑71.4%	22↑21.8%
Net Change in Cash	59	59↓0.0%	-55↓192.5%	4↑107.4%	39↑866.1%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance